Research Analysts’ Recent Ratings Updates for Soleno Therapeutics (SLNO)

Soleno Therapeutics (NASDAQ: SLNO) has recently received a number of price target changes and ratings updates:

• 1/22/2026 – Soleno Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Soleno Therapeutics had its “overweight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $114.00 price target on the stock, up previously from $106.00.
• 1/20/2026 – Soleno Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock, up previously from $110.00.
• 1/13/2026 – Soleno Therapeutics was given a new $107.00 price target on by analysts at Robert W. Baird.
• 1/12/2026 – Soleno Therapeutics was given a new $60.00 price target on by analysts at Wolfe Research.
• 1/12/2026 – Soleno Therapeutics had its “outperform” rating reaffirmed by analysts at Wolfe Research.
• 1/5/2026 – Soleno Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.